ABEO
USDAbeona Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$6.200
Kõrge
$6.310
Madal
$6.100
Maht
0.72M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
319.5M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.67M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19
Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics with a Outperform rating and announces Price Target of $19.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in
Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20
Stifel analyst Dae Gon Ha maintains Abeona Therapeutics with a Buy and lowers the price target from $21 to $20.
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.